Mobic ads cited for implying superiority
Executive Summary
Boehringer Ingelheim newspaper ad for its COX-2 inhibitor Mobic (meloxicam) implies superiority to Merck's Vioxx and Pfizer/Pharmacia's Celebrex, FDA ad division letter says. The ad's "rhetorical question 'Are You Dissatisfied?' implies clinical superiority of Mobic compared with Vioxx or Celebrex in osteoarthritis," the letter says. The ad also makes unsubstantiated claims about international use of the drug and presents risk information in a manner only comprehensible to healthcare professionals, the Oct. 24 letter says...